{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T21:12:27Z","timestamp":1788642747067,"version":"build-2803163510"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40123-026-01476-0","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:25:24Z","timestamp":1786627524000},"page":"3225-3243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Wnt Pathway Agonism as a Therapeutic Strategy for Retinal Vascular Diseases: A Narrative Review of Evidence to Date"],"prefix":"10.1007","volume":"15","author":[{"given":"Stephane","family":"Angers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Antonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald J.","family":"Junge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nudleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Nagiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio G.","family":"Schlottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Prenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Guyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Rekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Adamis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4982-1999","authenticated-orcid":false,"given":"Yin Shan Eric","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"21","key":"1476_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111877","volume":"22","author":"F Yemanyi","year":"2021","unstructured":"Yemanyi F, Bora K, Blomfield AK, Wang Z, Chen J. Wnt signaling in inner blood\u2013retinal barrier maintenance. Int J Mol Sci. 2021;22(21):11877.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1476_CR2","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/febs.16330","volume":"290","author":"F O\u2019Leary","year":"2023","unstructured":"O\u2019Leary F, Campbell M. The blood-retina barrier in health and disease. FEBS J. 2023;290(4):878\u201391.","journal-title":"FEBS J"},{"key":"1476_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.visres.2017.05.009","volume":"139","author":"M Diaz-Coranguez","year":"2017","unstructured":"Diaz-Coranguez M, Ramos C, Antonetti DA. The inner blood\u2013retinal barrier: cellular basis and development. Vision Res. 2017;139:123\u201337.","journal-title":"Vision Res"},{"key":"1476_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2024.101245","volume":"99","author":"O Tomkins-Netzer","year":"2024","unstructured":"Tomkins-Netzer O, Niederer R, Greenwood J, Fabian ID, Serlin Y, Friedman A, et al. Mechanisms of blood\u2013retinal barrier disruption related to intraocular inflammation and malignancy. Prog Retin Eye Res. 2024;99:101245.","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"1476_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41574-020-00451-4","volume":"17","author":"DA Antonetti","year":"2021","unstructured":"Antonetti DA, Silva PS, Stitt AW. Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat Rev Endocrinol. 2021;17(4):195\u2013206.","journal-title":"Nat Rev Endocrinol"},{"key":"1476_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/978-981-13-7647-4_10","volume":"1141","author":"L Liu","year":"2019","unstructured":"Liu L, Liu X. Roles of drug transporters in blood\u2013retinal barrier. Adv Exp Med Biol. 2019;1141:467\u2013504.","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"1476_CR7","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202113977","volume":"13","author":"R Chidiac","year":"2021","unstructured":"Chidiac R, Abedin M, Macleod G, Yang A, Thibeault PE, Blazer LL, et al. A Norrin\/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathy. EMBO Mol Med. 2021;13(7):e13977.","journal-title":"EMBO Mol Med"},{"issue":"6","key":"1476_CR8","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.3390\/nu7064453","volume":"7","author":"GW Go","year":"2015","unstructured":"Go GW. Low-density lipoprotein receptor-related protein 6 (LRP6) is a novel nutritional therapeutic target for hyperlipidemia, non-alcoholic fatty liver disease, and atherosclerosis. Nutrients. 2015;7(6):4453\u201364.","journal-title":"Nutrients"},{"key":"1476_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.preteyeres.2018.11.008","volume":"70","author":"Z Wang","year":"2019","unstructured":"Wang Z, Liu CH, Huang S, Chen J. Wnt signaling in vascular eye diseases. Prog Retin Eye Res. 2019;70:110\u201333.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"1476_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt\/beta-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"1476_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/15216540500137586","volume":"57","author":"AS Hackam","year":"2005","unstructured":"Hackam AS. The Wnt signaling pathway in retinal degenerations. IUBMB Life. 2005;57(6):381\u20138.","journal-title":"IUBMB Life"},{"issue":"1","key":"1476_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/scd.2008.0169","volume":"18","author":"EM Lad","year":"2009","unstructured":"Lad EM, Cheshier SH, Kalani MY. Wnt-signaling in retinal development and disease. Stem Cells Dev. 2009;18(1):7\u201316.","journal-title":"Stem Cells Dev"},{"key":"1476_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/EB.S94452","volume":"8","author":"KA Drenser","year":"2016","unstructured":"Drenser KA. Wnt signaling pathway in retinal vascularization. Eye Brain. 2016;8:141\u20136.","journal-title":"Eye Brain"},{"issue":"11","key":"1476_CR14","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.3390\/pharmaceutics14112476","volume":"14","author":"H Nguyen","year":"2022","unstructured":"Nguyen H, Lee SJ, Li Y. Selective activation of the Wnt-signaling pathway as a novel therapy for the treatment of diabetic retinopathy and other retinal vascular diseases. Pharmaceutics. 2022;14(11):2476.","journal-title":"Pharmaceutics"},{"issue":"4","key":"1476_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041219","volume":"12","author":"ML Bats","year":"2022","unstructured":"Bats ML, Peghaire C, Delobel V, Dufourcq P, Couffinhal T, Dupl\u00e0a C. Wnt\/frizzled signaling in endothelium: a major player in blood\u2013retinal- and blood\u2013brain\u2013barrier integrity. Cold Spring Harb Perspect Med. 2022;12(4):a041219.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"1476_CR16","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cell.2012.10.042","volume":"151","author":"Y Wang","year":"2012","unstructured":"Wang Y, Rattner A, Zhou Y, Williams J, Smallwood PM, Nathans J. Norrin\/Frizzled4 signaling in retinal vascular development and blood brain barrier plasticity. Cell. 2012;151(6):1332\u201344.","journal-title":"Cell"},{"issue":"S1","key":"1476_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.00623","volume":"34","author":"K Hollis","year":"2020","unstructured":"Hollis K, Zhong A, Stevens P, Diegel C, Michalski M, Williams B. WNT receptor requirements for dishevelled phosphorylation. FASEB J. 2020;34(S1):1.","journal-title":"FASEB J"},{"issue":"11","key":"1476_CR18","doi-asserted-by":"publisher","first-page":"6789","DOI":"10.1074\/jbc.M114.612648","volume":"290","author":"JP Dijksterhuis","year":"2015","unstructured":"Dijksterhuis JP, Baljinnyam B, Stanger K, Sercan HO, Ji Y, Andres O, et al. Systematic mapping of WNT-FZD protein interactions reveals functional selectivity by distinct WNT-FZD pairs. J Biol Chem. 2015;290(11):6789\u201398.","journal-title":"J Biol Chem"},{"issue":"8","key":"1476_CR19","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.4103\/1673-5374.303010","volume":"16","author":"S Kassumeh","year":"2021","unstructured":"Kassumeh S, Weber GR, Nobl M, Priglinger SG, Ohlmann A. The neuroprotective role of Wnt signaling in the retina. Neural Regen Res. 2021;16(8):1524\u20138.","journal-title":"Neural Regen Res"},{"key":"1476_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.visres.2017.02.007","volume":"139","author":"Q Chen","year":"2017","unstructured":"Chen Q, Ma JX. Canonical Wnt signaling in diabetic retinopathy. Vis Res. 2017;139:47\u201358.","journal-title":"Vision Res"},{"issue":"2","key":"1476_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2009.07.047","volume":"139","author":"X Ye","year":"2009","unstructured":"Ye X, Wang Y, Cahill H, Yu M, Badea TC, Smallwood PM, et al. Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization. Cell. 2009;139(2):285\u201398.","journal-title":"Cell"},{"issue":"13","key":"1476_CR22","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.celrep.2017.06.004","volume":"19","author":"MB Lai","year":"2017","unstructured":"Lai MB, Zhang C, Shi J, Johnson V, Khandan L, McVey J, et al. TSPAN12 is a Norrin co-receptor that amplifies Frizzled4 ligand selectivity and signaling. Cell Rep. 2017;19(13):2809\u201322.","journal-title":"Cell Rep"},{"issue":"2","key":"1476_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.cell.2009.07.048","volume":"139","author":"HJ Junge","year":"2009","unstructured":"Junge HJ, Yang S, Burton JB, Paes K, Shu X, French DM, et al. TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4\/beta-catenin signaling. Cell. 2009;139(2):299\u2013311.","journal-title":"Cell"},{"issue":"3","key":"1476_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nn.3032","volume":"15","author":"S Siegert","year":"2012","unstructured":"Siegert S, Cabuy E, Scherf BG, Kohler H, Panda S, Le YZ, et al. Transcriptional code and disease map for adult retinal cell types. Nat Neurosci. 2012;15(3):487\u201395 (S1\u20132).","journal-title":"Nat Neurosci"},{"issue":"3","key":"1476_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152833","volume":"11","author":"W Huang","year":"2016","unstructured":"Huang W, Li Q, Amiry-Moghaddam M, Hokama M, Sardi SH, Nagao M, et al. Critical endothelial regulation by LRP5 during retinal vascular development. PLoS ONE. 2016;11(3):e0152833.","journal-title":"PLoS ONE"},{"issue":"11","key":"1476_CR26","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1161\/ATVBAHA.118.311689","volume":"38","author":"C Zhang","year":"2018","unstructured":"Zhang C, Lai MB, Pedler MG, Johnson V, Adams RH, Petrash JM, et al. Endothelial cell-specific inactivation of TSPAN12 (Tetraspanin 12) reveals pathological consequences of barrier defects in an otherwise intact vasculature. Arterioscler Thromb Vasc Biol. 2018;38(11):2691\u2013705.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"50","key":"1476_CR27","doi-asserted-by":"publisher","first-page":"E11827","DOI":"10.1073\/pnas.1813217115","volume":"115","author":"Y Wang","year":"2018","unstructured":"Wang Y, Cho C, Williams J, Smallwood PM, Zhang C, Junge HJ, et al. Interplay of the Norrin and Wnt7a\/Wnt7b signaling systems in blood-brain barrier and blood-retina barrier development and maintenance. Proc Natl Acad Sci USA. 2018;115(50):E11827\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1476_CR28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1073\/pnas.0805165106","volume":"106","author":"R Daneman","year":"2009","unstructured":"Daneman R, Agalliu D, Zhou L, Kuhnert F, Kuo CJ, Barres BA. Wnt\/\u03b2-catenin signaling is required for CNS, but not non-CNS, angiogenesis. Proc Natl Acad Sci USA. 2009;106(2):641\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"19","key":"1476_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cells12192402","volume":"12","author":"M Diaz-Coranguez","year":"2023","unstructured":"Diaz-Coranguez M, Gonzalez-Gonzalez L, Wang A, Liu X, Antonetti DA. Disheveled-1 interacts with claudin-5 and contributes to Norrin-induced endothelial barrier restoration. Cells. 2023;12(19):2402.","journal-title":"Cells"},{"issue":"2","key":"1476_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021575","volume":"24","author":"L Di Bartolomeo","year":"2023","unstructured":"Di Bartolomeo L, Vaccaro F, Irrera N, Borgia F, Li Pomi F, Squadrito F, et al. Wnt signaling pathways: from inflammation to non-melanoma skin cancers. Int J Mol Sci. 2023;24(2):1575.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"1476_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells12212579","volume":"12","author":"V Le","year":"2023","unstructured":"Le V, Abdelmessih G, Dailey WA, Pinnock C, Jobczyk V, Rashingkar R, et al. Mechanisms underlying rare inherited pediatric retinal vascular diseases: FEVR, Norrie disease, persistent fetal vascular syndrome. Cells. 2023;12(21):2579.","journal-title":"Cells"},{"issue":"8","key":"1476_CR32","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.18240\/ijo.2022.08.11","volume":"15","author":"HF Qin","year":"2022","unstructured":"Qin HF, Shi FJ, Zhang CY, Luo DW, Qin SY, Wu J, et al. Anti-VEGF reduces inflammatory features in macular edema secondary to retinal vein occlusion. Int J Ophthalmol. 2022;15(8):1296\u2013304.","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"1476_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03665-6","volume":"24","author":"M Benhamza","year":"2024","unstructured":"Benhamza M, Dahlui M, Said MA. Determining direct, indirect healthcare and social costs for diabetic retinopathy management: a systematic review. BMC Ophthalmol. 2024;24(1):424.","journal-title":"BMC Ophthalmol"},{"issue":"10","key":"1476_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102346","volume":"12","author":"V Barone","year":"2024","unstructured":"Barone V, Surico PL, Cutrupi F, Mori T, Gallo Afflitto G, Di Zazzo A, et al. The role of immune cells and signaling pathways in diabetic eye disease: a comprehensive review. Biomedicines. 2024;12(10):2346.","journal-title":"Biomedicines"},{"issue":"4","key":"1476_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19040942","volume":"19","author":"A Rubsam","year":"2018","unstructured":"Rubsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19(4):942.","journal-title":"Int J Mol Sci"},{"key":"1476_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1055087","volume":"13","author":"T Yue","year":"2022","unstructured":"Yue T, Shi Y, Luo S, Weng J, Wu Y, Zheng X. The role of inflammation in immune system of diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Front Immunol. 2022;13:1055087.","journal-title":"Front Immunol"},{"issue":"1","key":"1476_CR37","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1159\/000534553","volume":"66","author":"T Santos","year":"2023","unstructured":"Santos T, Santos AR, Almeida AC, Rocha AC, Reste-Ferreira D, Marques IP, et al. Retinal capillary nonperfusion in preclinical diabetic retinopathy. Ophthalmic Res. 2023;66(1):1327\u201334.","journal-title":"Ophthalmic Res"},{"issue":"4","key":"1476_CR38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789\u2013801.","journal-title":"Ophthalmology"},{"issue":"3","key":"1476_CR39","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2337\/diabetes.55.03.06.db05-1349","volume":"55","author":"T Pannicke","year":"2006","unstructured":"Pannicke T, Iandiev I, Wurm A, Uckermann O, vom Hagen F, Reichenbach A, et al. Diabetes alters osmotic swelling characteristics and membrane conductance of glial cells in rat retina. Diabetes. 2006;55(3):633\u20139.","journal-title":"Diabetes"},{"issue":"2","key":"1476_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2337\/db16-0051","volume":"66","author":"JC Portillo","year":"2017","unstructured":"Portillo JC, Lopez Corcino Y, Miao Y, Tang J, Sheibani N, Kern TS, et al. CD40 in retinal Muller cells induces P2X7-dependent cytokine expression in macrophages\/microglia in diabetic mice and development of early experimental diabetic retinopathy. Diabetes. 2017;66(2):483\u201393.","journal-title":"Diabetes"},{"issue":"12","key":"1476_CR41","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1096\/fj.03-1476fje","volume":"18","author":"AM Joussen","year":"2004","unstructured":"Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18(12):1450\u20132.","journal-title":"FASEB J"},{"issue":"1","key":"1476_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2(1):17.","journal-title":"Eye Vis (Lond)"},{"issue":"6","key":"1476_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060449","volume":"11","author":"S Sen","year":"2021","unstructured":"Sen S, Ramasamy K, Sivaprasad S. Indicators of visual prognosis in diabetic macular oedema. J Pers Med. 2021;11(6):449.","journal-title":"J Pers Med"},{"issue":"11","key":"1476_CR44","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.ophtha.2008.08.023","volume":"115","author":"R Klein","year":"2008","unstructured":"Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859\u201368.","journal-title":"Ophthalmology"},{"issue":"3-4","key":"1476_CR45","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12031-017-0947-4","volume":"62","author":"A Vall\u00e9e","year":"2017","unstructured":"Vall\u00e9e A, Lecarpentier Y, Guillevin R, Vall\u00e9e JN. Aerobic glycolysis hypothesis through WNT\/beta-catenin pathway in exudative age-related macular degeneration. J Mol Neurosci. 2017;62(3\u20134):368\u201379.","journal-title":"J Mol Neurosci"},{"issue":"1","key":"1476_CR46","doi-asserted-by":"publisher","first-page":"19718","DOI":"10.1038\/s41598-019-56075-w","volume":"9","author":"MD Laksitorini","year":"2019","unstructured":"Laksitorini MD, Yathindranath V, Xiong W, Hombach-Klonisch S, Miller DW. Modulation of Wnt\/beta-catenin signaling promotes blood-brain barrier phenotype in cultured brain endothelial cells. Sci Rep. 2019;9(1):19718.","journal-title":"Sci Rep"},{"issue":"1","key":"1476_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/biomedicines13010105","volume":"13","author":"DM Darabu\u015f","year":"2025","unstructured":"Darabu\u015f DM, D\u0103r\u0103bu\u015f RG, Munteanu M. The diagnosis and treatment of branch retinal vein occlusions: an update. Biomedicines. 2025;13(1):105.","journal-title":"Biomedicines"},{"issue":"2","key":"1476_CR48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313-9.e1.","journal-title":"Ophthalmology"},{"issue":"5","key":"1476_CR49","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/s41433-024-03529-9","volume":"39","author":"DJ Fu","year":"2025","unstructured":"Fu DJ, Mishra AV, Quek C, Balaskas K, Pontikos N, Sim D, et al. Visual and anatomical failure of anti-VEGF therapy for retinal vascular diseases: a survival analysis of real-world data. Eye (Lond). 2025;39(5):977\u201385.","journal-title":"Eye (Lond)"},{"issue":"1","key":"1476_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40942-023-00453-0","volume":"9","author":"RL Gurung","year":"2023","unstructured":"Gurung RL, FitzGerald LM, Liu E, McComish BJ, Kaidonis G, Ridge B, et al. Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice. Int J Retina Vitreous. 2023;9(1):23.","journal-title":"Int J Retina Vitreous"},{"issue":"5","key":"1476_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051049","volume":"10","author":"JO Wallsh","year":"2021","unstructured":"Wallsh JO, Gallemore RP. Anti-VEGF-resistant retinal diseases: a review of the latest treatment options. Cells. 2021;10(5):1049.","journal-title":"Cells"},{"key":"1476_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2022.108945","volume":"216","author":"HL Deissler","year":"2022","unstructured":"Deissler HL, Rehak M, Busch C, Wolf A. Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells. Exp Eye Res. 2022;216:108945.","journal-title":"Exp Eye Res"},{"issue":"11","key":"1476_CR53","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1167\/iovs.06-0403","volume":"47","author":"H Liu","year":"2006","unstructured":"Liu H, Thurig S, Mohamed O, Dufort D, Wallace VA. Mapping canonical Wnt signaling in the developing and adult retina. Invest Ophthalmol Vis Sci. 2006;47(11):5088\u201397.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1476_CR54","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0092-8674(04)00216-8","volume":"116","author":"Q Xu","year":"2004","unstructured":"Xu Q, Wang Y, Dabdoub A, Smallwood PM, Williams J, Woods C, et al. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell. 2004;116(6):883\u201395.","journal-title":"Cell"},{"issue":"12","key":"1476_CR55","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/hmg\/dds087","volume":"21","author":"J Zuercher","year":"2012","unstructured":"Zuercher J, Fritzsche M, Feil S, Mohn L, Berger W. Norrin stimulates cell proliferation in the superficial retinal vascular plexus and is pivotal for the recruitment of mural cells. Hum Mol Genet. 2012;21(12):2619\u201330.","journal-title":"Hum Mol Genet"},{"issue":"9","key":"1476_CR56","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1172\/JCI76431","volume":"124","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Wang Y, Tischfield M, Williams J, Smallwood PM, Rattner A, et al. Canonical WNT signaling components in vascular development and barrier formation. J Clin Invest. 2014;124(9):3825\u201346.","journal-title":"J Clin Invest"},{"issue":"1","key":"1476_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030203","volume":"7","author":"J Chen","year":"2012","unstructured":"Chen J, Stahl A, Krah NM, Seaward MR, Joyal JS, Juan AM, et al. Retinal expression of Wnt-pathway mediated genes in low-density lipoprotein receptor-related protein 5 (Lrp5) knockout mice. PLoS ONE. 2012;7(1):e30203.","journal-title":"PLoS ONE"},{"issue":"2","key":"1476_CR58","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1167\/iovs.08-1731","volume":"50","author":"NF Schafer","year":"2009","unstructured":"Schafer NF, Luhmann UF, Feil S, Berger W. Differential gene expression in Ndph-knockout mice in retinal development. Invest Ophthalmol Vis Sci. 2009;50(2):906\u201316.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1476_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24476-y","volume":"8","author":"SC Beck","year":"2018","unstructured":"Beck SC, Karlstetter M, Garcia Garrido M, Feng Y, Dannhausen K, Muhlfriedel R, et al. Cystoid edema, neovascularization and inflammatory processes in the murine Norrin-deficient retina. Sci Rep. 2018;8(1):5970.","journal-title":"Sci Rep"},{"key":"1476_CR60","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.43257","volume":"8","author":"Y Wang","year":"2019","unstructured":"Wang Y, Sabbagh MF, Gu X, Rattner A, Williams J, Nathans J. Beta-catenin signaling regulates barrier-specific gene expression in circumventricular organ and ocular vasculatures. Elife. 2019;8:e43257.","journal-title":"Elife"},{"issue":"9","key":"1476_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1167\/tvst.11.9.19","volume":"11","author":"H Nguyen","year":"2022","unstructured":"Nguyen H, Chen H, Vuppalapaty M, Whisler E, Logas KR, Sampathkumar P, et al. SZN-413, a FZD4 agonist, as a potential novel therapeutic for the treatment of diabetic retinopathy. Transl Vis Sci Technol. 2022;11(9):19.","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"1476_CR62","doi-asserted-by":"publisher","first-page":"9802","DOI":"10.1038\/s41598-020-66092-9","volume":"10","author":"W Yan","year":"2020","unstructured":"Yan W, Peng YR, van Zyl T, Regev A, Shekhar K, Juric D, et al. Cell atlas of the human fovea and peripheral retina. Sci Rep. 2020;10(1):9802.","journal-title":"Sci Rep"},{"issue":"1","key":"1476_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/eye.2014.70","volume":"29","author":"DF Gilmour","year":"2015","unstructured":"Gilmour DF. Familial exudative vitreoretinopathy and related retinopathies. Eye (Lond). 2015;29(1):1\u201314.","journal-title":"Eye (Lond)"},{"key":"1476_CR64","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.visres.2017.03.006","volume":"139","author":"TW Gardner","year":"2017","unstructured":"Gardner TW, Sundstrom JM. A proposal for early and personalized treatment of diabetic retinopathy based on clinical pathophysiology and molecular phenotyping. Vis Res. 2017;139:153\u201360.","journal-title":"Vis Res"},{"issue":"8","key":"1476_CR65","first-page":"886","volume":"66","author":"AA Dreffs","year":"2025","unstructured":"Dreffs AA, Hendry E, Gonzalez L, Lin C-M, Diaz Coranguez M, Antonetti DA. Norrin treatment prevents vascular permeability and amacrine cell loss while preserving vision in diabetic rats. Investig Ophthal Visl Sci. 2025;66(8):886.","journal-title":"Investig Ophthal Visl Sci."},{"issue":"12","key":"1476_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189857","volume":"12","author":"W Halfter","year":"2017","unstructured":"Halfter W, Moes S, Asgeirsson DO, Halfter K, Oertle P, Melo Herraiz E, et al. Diabetes-related changes in the protein composition and the biomechanical properties of human retinal vascular basement membranes. PLoS ONE. 2017;12(12):e0189857.","journal-title":"PLoS ONE"},{"issue":"6","key":"1476_CR67","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.2353\/ajpath.2009.080945","volume":"175","author":"Y Chen","year":"2009","unstructured":"Chen Y, Hu Y, Zhou T, Zhou KK, Mott R, Wu M, et al. Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol. 2009;175(6):2676\u201385.","journal-title":"Am J Pathol"},{"issue":"7","key":"1476_CR68","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2337\/db20-1220","volume":"70","author":"A Goncalves","year":"2021","unstructured":"Goncalves A, Dreffs A, Lin C-m, Sheskey S, Hudson N, Keil J, et al. Vascular expression of permeability-resistant occludin mutant preserves visual function in diabetes. Diabetes. 2021;70(7):1549\u201360.","journal-title":"Diabetes"},{"issue":"14","key":"1476_CR69","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1074\/jbc.RA119.011273","volume":"295","author":"M D\u00edaz-Cor\u00e1nguez","year":"2020","unstructured":"D\u00edaz-Cor\u00e1nguez M, Lin CM, Liebner S, Antonetti DA. Norrin restores blood\u2013retinal barrier properties after vascular endothelial growth factor-induced permeability. J Biol Chem. 2020;295(14):4647\u201360.","journal-title":"J Biol Chem"},{"issue":"21","key":"1476_CR70","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1101\/gad.228544.113","volume":"27","author":"J Ke","year":"2013","unstructured":"Ke J, Harikumar KG, Erice C, Chen C, Gu X, Wang L, et al. Structure and function of Norrin in assembly and activation of a Frizzled 4-Lrp5\/6 complex. Genes Dev. 2013;27(21):2305\u201319.","journal-title":"Genes Dev"},{"key":"1476_CR71","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.46134","volume":"8","author":"Y Tao","year":"2019","unstructured":"Tao Y, Mis M, Blazer L, Ustav MJ, Steinhart Z, Chidiac R, et al. Tailored tetravalent antibodies potently and specifically activate Wnt\/Frizzled pathways in cells, organoids and mice. Elife. 2019;8:e46134.","journal-title":"Elife"},{"issue":"8","key":"1476_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107415","volume":"26","author":"L Zhang","year":"2023","unstructured":"Zhang L, Abedin M, Jo H-N, Levey J, Dinh QC, Chen Z, et al. A Frizzled4-LRP5 agonist promotes blood-retina barrier function by inducing a Norrin-like transcriptional response. IScience. 2023;26(8):107415.","journal-title":"IScience"},{"issue":"22","key":"1476_CR73","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.190227","volume":"10","author":"L Zhang","year":"2025","unstructured":"Zhang L, Levey J, Abedin M, Jo HN, Odame E, Howe M, et al. C1q limits cystoid edema by maintaining basal \u03b2-catenin-dependent signaling and blood-retina barrier function. JCI Insight. 2025;10(22):e190227.","journal-title":"JCI Insight"},{"issue":"6","key":"1476_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109938","volume":"27","author":"Y Post","year":"2024","unstructured":"Post Y, Lu C, Fletcher RB, Yeh WC, Nguyen H, Lee SJ, et al. Design principles and therapeutic applications of novel synthetic WNT signaling agonists. iScience. 2024;27(6):109938.","journal-title":"iScience"},{"key":"1476_CR75","unstructured":"Biotechnologies. N. Neuvasq is engineering and developing antibodies that activate the Wnt pathway. 2025. Available from: https:\/\/neuvasq.com\/pipeline\/."},{"issue":"8","key":"1476_CR76","first-page":"2635","volume":"66","author":"S Lee","year":"2025","unstructured":"Lee S, Fan Y, Yang Y, Suen N, Ye J, Chen H, et al. SZN-8141, a Norrin mimetic and an anti-VEGF fusion molecule, as a novel candidate for retinopathy therapeutics. Invest Ophthalmol Vis Sci. 2025;66(8):2635.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1476_CR77","unstructured":"Wu Y, Ye W, Burton J, Chiu C, inventors; Genentech, Inc., assignee. Method of treating retinopathy with an anti-LRP5 antibody. US Patent No. 10,035,854 Published July 31, 2018."},{"issue":"8","key":"1476_CR78","first-page":"5969","volume":"66","author":"R Laufer","year":"2025","unstructured":"Laufer R, Gu\u00e9rit S, Strzelczyk P, Progneaux A, Vogel I, Thielens S, et al. Engineered Gpr124- and Reck-targeting Wnt surrogates activate \u03b2-catenin signaling in the blood-retina barrier and reverse disease phenotypes in vascular retinopathy models. Invest Ophthalmol Vis Sci. 2025;66(8):5969.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1476_CR79","unstructured":"A 2-part study consisting of multiple ascending dose (MAD) safety study, and a dose-finding masked study to assess the safety and efficacy of intravitreal (IVT) EYE103 in patients with diabetic macular edema (DME) or neovascular age-related macular degeneration (NVAMD) (AMARONE). [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05919693."},{"key":"1476_CR80","unstructured":"Miller CG. Restoret (EYE103\/MK3000) for the treatment of diabetic macular edema: results from the AMARONE phase 1b\/2a clinical trial. Presented at: International MaculArt Meeting; June 29 to July 1, 2025; Paris, France."},{"key":"1476_CR81","unstructured":"A study to evaluate the efficacy and safety of 2 doses of EYE103 compared with ranibizumab (0.5 mg) in participants with DME (BRUNELLO). [Internet]. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06571045."},{"key":"1476_CR82","unstructured":"A study of 2 doses of EYE103 compared with ranibizumab (0.5 mg) in participants with DME (BAROLO). [Internet]. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06957080."},{"key":"1476_CR83","unstructured":"A dose-masked study of intravitreal EYE103 in participants with NVAMD or macular edema following BRVO (Super Tuscan). [Internet]. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07205887."},{"key":"1476_CR84","unstructured":"Ye W, Burton J, Wu Y, Chiu C, inventors; Genentech, Inc., assignee. Anti-LRP5 antibodies and methods of use patent WO 2013\/109818 A1. Published July 25, 2013."},{"issue":"3","key":"1476_CR85","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10456-010-9184-y","volume":"13","author":"MV Hoang","year":"2010","unstructured":"Hoang MV, Smith LE, Senger DR. Moderate GSK-3beta inhibition improves neovascular architecture, reduces vascular leakage, and reduces retinal hypoxia in a model of ischemic retinopathy. Angiogenesis. 2010;13(3):269\u201377.","journal-title":"Angiogenesis"},{"key":"1476_CR86","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fnmol.2011.00040","volume":"4","author":"O Kaidanovich-Beilin","year":"2011","unstructured":"Kaidanovich-Beilin O, Woodgett JR. GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci. 2011;4:40.","journal-title":"Front Mol Neurosci"},{"issue":"12","key":"1476_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/cells11121950","volume":"11","author":"MZ Chauhan","year":"2022","unstructured":"Chauhan MZ, Rather PA, Samarah SM, Elhusseiny AM, Sallam AB. Current and novel therapeutic approaches for treatment of diabetic macular edema. Cells. 2022;11(12):1950.","journal-title":"Cells"},{"key":"1476_CR88","unstructured":"Wykoff C. Restoret (EYE103) for the treatment of diabetic macular edema and neovascular AMD: first-time extended results from the AMARONE Phase 1b\/2a clinical trial. In: Presented at: The 128th Annual Meeting of the American Academy of Ophthalmology; October 18\u201321, 2024; Chicago, IL, USA."},{"issue":"14","key":"1476_CR89","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1038\/s41433-023-02439-6","volume":"37","author":"PAH Nichani","year":"2023","unstructured":"Nichani PAH, Popovic MM, Dhoot AS, Pathak A, Muni RH, Kertes PJ. Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis. Eye (Lond). 2023;37(14):2855\u201363.","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01476-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01476-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01476-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T21:02:50Z","timestamp":1788642170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01476-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":89,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1476"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01476-0","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephane Angers is a shareholder of AntlerA Therapeutics (now a subsidiary of Roche). Charles C. Wykoff is a consultant for or has received research support from Boehringer Ingelheim, EyeBio\/MSD, and Surrozen. David A. Antonetti is a consultant for EyeBio, Maze Therapeutics, ONL Therapeutics, and Venrock. Harald J. Junge is a former consultant and scientific advisory board member for AntlerA Therapeutics (now a subsidiary of Roche). Eric Nudleman is a consultant for Alcon, EyeBio\/MSD, Genentech\/Roche, and Kalaris. Aaron Nagiel is a consultant for AAvantgarde, Blue Gen, BlueRock, Cellio, Endogena, Epicrispr, EyeBio, Janssen, Opus, RareSight, and Ultragenyx and has received research support from Atsena, Beacon, Genentech, and J&J. Patricio G. Schlottmann is a consultant for EyeBio\/MSD and Genentech. Donald J. D\u2019Amico is a consultant for EyeBio\/MSD and Kalaris and has equity in EyeBio\/MSD. Jonathan Prenner is a consultant for Merck and serves on the board of directors for and may own stock or hold stock options in Bionic Sight and Ripple Therapeutics. David R. Guyer, Charles G. Miller, Keith Baker, Paul Stephens, Anthony P. Adamis, and Yin Shan Eric Ng are employees of EyeBio, a wholly owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and may own stock or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. Erin Henry and Hans Rekers are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and may own stock or hold stock options in Merck & Co., Inc., Rahway, NJ, USA.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}